Pucotenlimab

Generic Name: Pucotenlimab

Drug Type: Biotech

CAS Number: 2403647-03-8

Unique Ingredient Identifier: CGA81G3KR5

Background: Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours. It is being investigated in other cancers.

Indication: 用于治疗微卫星高度不稳定╱错配修复缺陷(MSI-H/dMMR)实体瘤的患者，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者；既往至少一线治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。

Clinical Trials

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

Phase 2

Not yet recruiting

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pucotenlimab
Drug: MRG003

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Target Recruit Count: 106

Registration Number: NCT06959108

The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC

Phase 2

Not yet recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Pucotenlimab

First Posted Date: 2025-03-26

Last Posted Date: 2025-03-26

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 30

Registration Number: NCT06895369

Locations: 🇨🇳
Sir Run Run Shaw Hospital, Hanzhou, Zhejiang, China

Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Rectal Adenocarcinoma

Interventions: Drug: Pucotenlimab
Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Trifluridine/Tipiracil Hydrochloride
Radiation: Short-course radiotherapy
Radiation: intracavitary brachytherapy

First Posted Date: 2025-03-12

Last Posted Date: 2025-03-12

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 33

Registration Number: NCT06872606

Locations: 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)

Phase 2

Not yet recruiting

Conditions: Rectal Cancer

Interventions: Drug: Pucotenlimab

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 68

Registration Number: NCT06770270

Clinical Efficacy Study of Pucotenlimab Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Phase 2

Not yet recruiting

Conditions: Endometrioid Endometrial Cancer

Interventions: Drug: Pucotenlimab
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Surgery

First Posted Date: 2024-08-20

Last Posted Date: 2024-08-20

Lead Sponsor: Women's Hospital School Of Medicine Zhejiang University

Target Recruit Count: 39

Registration Number: NCT06561308

Locations: 🇨🇳
Women's hospital school of medicine zhejiang university, Hangzhou, Zhejiang, China

Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen

Phase 1

Recruiting

Conditions: Rhabdomyosarcoma
Pediatric Cancer

Interventions: Drug: Pucotenlimab

First Posted Date: 2024-06-13

Last Posted Date: 2024-06-13

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 82

Registration Number: NCT06456892

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Pucotenlimab Combined With Lenvatinib

First Posted Date: 2023-11-13

Last Posted Date: 2023-11-13

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 47

Registration Number: NCT06129955

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Other (Non U.s.), China

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Phase 3

Not yet recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: HX008
Drug: Investigator's Choice Chemotherapy

First Posted Date: 2022-12-15

Last Posted Date: 2022-12-15

Lead Sponsor: Taizhou Hanzhong biomedical co. LTD

Target Recruit Count: 190

Registration Number: NCT05652894

Locations: 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Tianjin People's Hospital, Tianjin, Tianjin, China

and more 7 locations

A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

Phase 1

Conditions: Advanced Solid Tumor

Interventions: Drug: HX008

First Posted Date: 2021-04-01

Last Posted Date: 2021-04-01

Lead Sponsor: Taizhou Hanzhong biomedical co. LTD

Target Recruit Count: 30

Registration Number: NCT04825392

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, China
🇨🇳
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Phase 1

Conditions: Melanoma

Interventions: Drug: HX008
Drug: LP002

First Posted Date: 2021-02-16

Last Posted Date: 2021-02-16

Lead Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd.

Target Recruit Count: 63

Registration Number: NCT04756934

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy